据了解，Provenge是中国企业在美国收购的唯一生物类原研药，也是中国企业在海外收购的唯一细胞免疫治疗药物。三胞集团表示，收购完成后，希望 ...

南京新百5月23日晚间公告，公司发行股份收购世鼎香港并募集配套资金的事项获证监会上市公司并购重组审核委员会审核通过。世鼎香港主要经营性 ...

7月30日，南京新百涨0.13%，成交额4.19亿元，换手率4.81%，总市值100.15亿元。 异动分析 细胞免疫治疗+基因测序+创新药+电子商务+养老概念 1、南京新百收购Dendreon获批，而Dendreon的核心产品Provenge是美国FDA批准上市的首个细胞免疫治疗药物，也是目前治疗前列腺癌的唯一细胞免疫治疗药物。 2、记者日前获悉，南京新百参股的新加坡主板上市公司Cordlife于 ...

7月23日， 南京新百 涨停，成交额2.56亿元，换手率2.96%，总市值101.63亿元。 2、南京新百收购Dendreon获批，而Dendreon的核心产品Provenge是美国FDA批准上市的首个细胞免疫治疗药物，也是目前治疗前列腺癌的唯一细胞免疫治疗药物。

观点网讯： 5月13日，南京新街口百货商店股份有限公司召开2024年度业绩暨现金分红说明会。 会上，董事、总经理张轩表示核心产品普列威（PROVENGE®）作为全球首个经FDA批准的DC细胞治疗药物，在中国已完成三期临床受试者入组，如进展顺利，预计2026年递交NDA上市申请。 报告期内，南京新百实现 ...

PROVENGE improved 3-year survival by 38% compared to placebo (31.7% versus 23.0%); Bear in mind that the price of Provenge is $50,000 a year, according to the WSJ.

Provenge extended median survival beyond two-years, demonstrating a median improvement of 4.1 months compared to the control group (25.8 months versus 21.7 months).

Interest in Dendreon Corp's Provenge vaccine to treat prostate cancer seems to be waning following recent approval of Johnson & Johnson's more-convenient and faster-acting Zytiga treatment ...

The Provenge story starts with studies at the Stanford University School of Medicine published in 1997 (J. Immunol. 159, 3113–3117) that showed that a cytotoxic T-lymphocyte (CTL) response to ...

If you're unwilling to even consider the cost of Provenge you're not serious about holding the line on health care costs, because stories like this happen nearly every day.

After trading, at 5.41 p.m., Dendreon puts out a statement that there will be an announcement regarding Provenge tomorrow. Tuesday April 14: Dendreon publishes positive news release in the morning.

Dendreon reports weak Provenge sales and says reimbursement issues will curtail growth for rest of year. shares fell sharply Wednesday night after the company reported weaker-than-expected ...